Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
$26.14
$0.24(1.85%)
At close: 4:00 PM EST
$26.14
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$5.90 - $29.60
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$300.26M
Enterprise Value$157.39M
Total Cash (Recent Filing)$89.25M
Total Debt (Recent Filing)$6.64M
Price to Earnings (P/E)0.7
Beta-0.15
Next Earnings
May 13, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.13
Shares Outstanding8,571,421
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue45.27
Enterprise Value/Gross Profit53.54
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$38.75Price Target Upside48.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.42
Revenue Forecast (FY)$1.31M
Bulls Say, Bears Say
Bulls Say
Mechanism/competitive DifferentiationA bi‑functional approach that activates Wnt signaling while trapping VEGF presents a differentiated mechanism that could enhance treatment durability compared with mono‑functional anti‑VEGF therapies.
Regulatory/IND MilestoneIND submission progress for SZN-8141 offers a clear regulatory catalyst that would advance the Wnt signaling program into formal clinical testing and clarify the development pathway.
Safety/platform De‑riskSuccessful GLP toxicology results for a partnered Wnt‑targeting compound provide external safety validation that reduces program risk across Surrozen's Wnt assets.
Bears Say
Clinical Outcome UncertaintyPivotal clinical outcomes for the Wnt agonist class remain uncertain, leaving development and commercial prospects dependent on forthcoming pivotal data.
Event‑driven VolatilityReliance on binary pivotal readouts for class de‑risking could produce sharp stock swings around trial announcements, making near‑term performance highly event‑driven.
Valuation And Investor RiskCompany valuation may face pressure because long‑term upside is contingent on successful pivotal results, creating elevated investment risk if trials fail or offer ambiguous readthroughs.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $5.90 and its highest was $29.59 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $300.26M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Mar 23, 2026. The company reported -$19.13 earnings per share for the quarter, missing the consensus estimate of -$1.288 by -$17.842.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.05.
How many shares outstanding does Surrozen have?
Surrozen has 8,571,421 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$19.13 in its last earnings report, missing expectations of -$1.288. Following the earnings report the stock price went down -0.951%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.75 (48.24% Upside)
$38.75 (48.24% Upside)
Hedge Fund Trend
Decreased
By 420.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
127.85%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$38.75
▲(48.24% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―